1293284-58-8

Basic information

• Product Name: Benzoic acid, 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, Methyl ester
• Synonyms: Benzoic acid, 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, Methyl ester;4-Fluoro-2-(Methoxycarbonyl)benzeneboronic acid pinacol ester, 96%;Methyl 5-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate
• CAS NO: 1293284-58-8
• Molecular Formula: C₁₄H₁₈BFO₄
• Molecular Weight: 298.1150032
• EINECS: -0
• Mol File: 1293284-58-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 365.6±37.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.14±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Benzoic acid, 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, Methyl ester(1293284-58-8)
• EPA Substance Registry System: Benzoic acid, 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, Methyl ester(1293284-58-8)

Safety Data

• Hazardous Substances Data: 1293284-58-8(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-, Methyl ester is a chemical compound that consists of a benzoic acid molecule with a 5-fluoro-2-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl) group and a methyl ester functional group. It is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various compounds. This chemical is known for its potential biological and pharmacological activities, and it is used as an intermediate in the production of active pharmaceutical ingredients and agrochemicals. Additionally, it serves as a substrate for various chemical reactions, making it a valuable tool for drug discovery and development.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 1202897-48-0 methyl 3-fluoro-6-iodobenzoate 
• 52548-63-7 5-fluoro-2-iodobenzoic acid 

Downstream Products

• 1293284-59-9 methyl 5-fluoro-2-(pyrimidin-2-yl)benzoate 
• 1293284-57-7 5-fluoro-2-(pyrimidin-2-yl)benzoic acid 

Relevant articles and documents

NOVEL N-(2,2-DIFLUOROETHYL)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES

The present invention relates to novel N-(2,2-difluoroehtyl)-N-[(Pyrimidinylamino)propanyl]- arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

CHEMICAL COMPOUNDS

The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group -O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro- benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: C1 C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicylic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.